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Abstract: The unfolded protein response (UPR) is an adaptive response to intrinsic and external
stressors, and it is mainly activated by the accumulation of misfolded proteins at the endoplasmic
reticulum (ER) lumen producing ER stress. The UPR signaling network is interconnected with
autophagy, the proteolytic machinery specifically devoted to clearing misfolded proteins in order to
survive bioenergetic stress and/or induce cell death. Oncosuppressor TP53 may undergo inactivation
following missense mutations within the DNA-binding domain (DBD), and mutant p53 (mutp53)
proteins may acquire a misfolded conformation, often due to the loss of the DBD-bound zinc ion,
leading to accumulation of hyperstable mutp53 proteins that correlates with more aggressive tumors,
resistance to therapies, and poorer outcomes. We previously showed that zinc supplementation
induces mutp53 protein degradation by autophagy. Here, we show that mutp53 (i.e., Arg273)
degradation following zinc supplementation is correlated with activation of ER stress and of the
IRE1α/XBPI arm of the UPR. ER stress inhibition with chemical chaperone 4-phenyl butyrate (PBA)
impaired mutp53 downregulation, which is similar to IRE1α/XBPI specific inhibition, reducing cancer
cell death. Knockdown of mutp53 failed to induce UPR/autophagy activation indicating that the
effect of zinc on mutp53 folding was likely the key event occurring in ER stress activation. Recently
discovered small molecules targeting components of the UPR show promise as a novel anticancer
therapeutic intervention. However, our findings showing UPR activation during mutp53 degradation
indicate that caution is necessary in the design of therapies that inhibit UPR components.
Keywords: p53; mutp53H273; autophagy; endoplasmic reticulum (ER) stress; IRE1α/XBP1; zinc
supplementation; 4-PBA; ST-083010; cancer therapy
1. Introduction
Tumor suppressor p53 plays a central role in tumor prevention and response to therapies.
The presence of a functional p53 pathway is incompatible with neoplastic growth and, for this reason,
p53 is the most frequently mutated gene in tumors [1]. The majority of p53 mutations are missense
mutations (i.e., R175H, R248Q, and R273H) that are mainly within the DNA-binding domain (DBD),
leading to the synthesis of p53 proteins that are unable to bind target gene promoters; however, some
mutant (mut) p53 proteins can physically bind other transcription factors, profoundly remodeling the
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cancer cell transcriptome and proteome [2]. Mouse models of different hotspot mutp53 proteins and
clinical data from germline and sporadic cancers have established that some mutp53 proteins not only
abolish the wild-type (wt) p53 tumor suppressive function, but can become oncogenic, promoting
invasion, metastasis, and chemoresistance [3,4]. Mutp53 proteins may acquire a misfolded and partially
denatured conformation, forming hyperstable micro- and macro-aggregates that cannot undergo
degradation, with their accumulation in tumors [5]. This aggregation may result from loss or alteration
of DBD-bound zinc, which is necessary for the thermodynamic stability of the DBD and is needed
for the wtp53 oncosuppressor function [6]. Preventing mutp53 accumulation provides an important
chemopreventive and chemotherapeutic anticancer strategy and, in the last few years, many small
molecules have been identified to induce mutp53 downregulation and/or reactivation of wtp53 (which
is inhibited by mutp53 as a dominant negative effect) [7,8]. Our previous studies showed that zinc
supplementation modifies the equilibrium between p53 mutant and wild-type conformation, positively
reactivating wtp53 functions of some of the most frequently p53 mutated residues, such as Arg175 and
Arg273 [9–12]. The reactivation of wtp53 conformation results in the re-establishment of canonical
DNA binding activity and the transcription of target genes, inducing apoptosis and inhibition of tumor
growth, in vitro and in animal models [9–12]. We also showed that a curcumin-based zinc complex [13]
induces mutp53 degradation through autophagy, in part depending on the wtp53-induced target gene
DRAM (damage-regulated autophagy modulator) [14–16], and in line with the notion that mutp53
blocks autophagy while wtp53 induces it [17].
Macroautophagy (hereafter indicated as autophagy), is a dynamic catabolic process that degrades
cytoplasmic components, unfolded proteins, and damaged organelles by enwrapping them into
lysosomes assisting cells to cope with stress load [18,19]. Autophagy can promote cell survival or
death. The process occurs at both the basal level and in response to stress, and it is linked to the
endoplasmic reticulum (ER) stress. ER, the principal intracellular organelle responsible for protein
folding, localization, and post-translational modifications, undergoes stress when unfolded proteins
accumulate into it due to intracellular and extracellular insults (i.e, glucose deprivation, hypoxia,
acidosis, inhibition of protein glycosylation, disturbance of intracellular Ca2+ stores, oncogenic mutation,
etc.). ER stress triggers the unfolded protein response (UPR) that, besides inducing autophagy, restores
ER homeostasis via the reduction of global protein synthesis and the activation of chaperones and
degradation processes [20]. UPR is orchestrated by three main sensors, namely inositol-requiring
enzyme 1α (IRE1α), activating transcription factor 6 (ATF6), and protein kinase RNA-like ER kinase
(PERK), which regulate many signaling pathways (autophagy, apoptosis, antioxidant response,
inflammation, etc.), and ultimately dictate cell survival or death decision [21]. The latter occurs when
the adaptive UPR response to stress is overwhelmed [22]. Under basal condition, the ER luminal
chaperone BiP/GRP78 protein binds to these UPR molecules from the ER lumen and suppresses their
basal activity. During ER stress, misfolded proteins accumulate in the ER lumen remove BiP from IRE1α,
PERK, and ATF-6, leading to activation of downstream signaling [23]. The IRE1α signaling pathway
induces expression of the transcription factor Xbp1s, which increases the expression of ER chaperons
and ER mass, stimulates lipid biogenesis, degrades unfolded proteins to enhance the secretory function
of ER, and triggers autophagy [24,25]. The activation of PERK can induce the pro-apoptotic function of
UPR through the eIF2α-ATF4-CHOP axis, but it can also induce autophagy, together with IRE1α/XBPI
and ATF6 arms [26]. UPR and autophagy are, thus, interconnected processes that share common
property to promote the adaption of cells to stress [27] and, for this reason, the dysregulation of one of
these processes strongly influences the other. Autophagy has been proposed as an innovative target
for anticancer therapies, although its manipulation in cancer is still debated [28]. In addition, targeting
specific components of the UPR signaling network is also becoming a novel potential anticancer
strategy [21]. Therefore, a better understanding of the interplay between UPR and autophagy may
help in elucidating the molecular mechanisms that tip the balance towards cell death or survival.
Based on these premises, we asked whether ER stress/UPR activation was involved in zinc-induced
mutp53 downregulation.
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2. Materials and Methods
2.1. Cell Culture and Reagents
The human U373MG (expressing R273H p53 mutation) and T98G (expressing M237I p53 mutation)
glioblastoma cell lines, and the HT29 (expressing R273H p53 mutation) and RKO (carrying wild-type
p53) colon cancer cell lines were maintained in RPM1-1640 (Life Technologies-Invitrogen); the human
HCT116 (carrying wild-type p53) colon cancer cell line was maintained in the Dulbecco modified Eagle’s
medium (DMEM) (Life Technologies-Invitrogen). All were supplemented with 10% heat-inactivated
fetal bovine serum (FBS) (Corning, NY, USA; 35-079) plus L-glutamine and streptomycin (100 µg/mL)
(Corning, NY, USA; 30-002), in 5% CO2 at 37 ◦C.
The following reagents were used: A heteroleptic pentacoordinated (bpy-9)Zn(curc, Cl) complex
containing a 4,4’-disubstituted-2,2’-bipyridine as the main ligand, and curcumin (curc) and chloride
(Cl) as ancillary ligands (Zn(II)-curc) [13], dissolved in DMSO and used at 100 µg/mL, as reported
in [12]; the inhibitor of wtp53 transactivation function pifithryn α (PFT-α) (Enzo Life Sciences, Lausen,
Switzerland, BML-GR325), dissolved in DMSO and used at 30 µM [15,29]; the ER stress inhibitor
4-Phenylbutyric acid (4-BPA) (Sigma-Aldrich, #P21005) [30], dissolved in filtered sterile water and used
at 2.5 mM; the ER stress inducer Tunicamycin (Tn) (Sigma-Aldrich, #T7765), dissolved in DMSO and
used at 1 µg/mL; and the inhibitor of XBP1 cleavage STF-083010 (Sigma-Aldrich, #SML0409) (hereafter
indicated as STF) [31,32], dissolved in DMSO and used at 60 µM.
2.2. Viability Assay and Cell Death/PI Staining
Subconfluent cells were plated in triplicate in six-well plates and, the day after, were treated with
Zn (II)-curc (100 µg/mL) for 24 h. Both adherent and floating cells were collected and cell viability
was assessed by Trypan blue (Sigma-Aldrich, #72571) exclusion counting blue (dead)/total cells with a
Neubauer hemocytometer using light microscopy.
Cell death was detected by cytofluorimetric analysis of propidium iodide (PI)-stained cells, as
previously reported [12]. Briefly, both floating and adherent cells were fixed in 80% ethanol and stained
in a PBS solution containing PI (62.5 mg/mL; Sigma-Aldrich, #P4864) and RNase A (1.125 mg/mL;
Sigma-Aldrich, #R6148). Samples were acquired with a FACScan instrument (Becton Dickinson) and
the percentage of cells in the sub-G1 compartment was calculated using ModFit LT software (Becton
Dickinson).
2.3. Endoplasmic Reticulum (ER) Staining
Subconfluent cells were seeded on coverslips in 35 mm Petri dishes and, the day after, were treated
with Zn (II)-curc (100 µg/mL) for 16 h. After treatment, cells were fixed with 3.7% paraformaldehyde
(Thermo Fisher Scientific, #50-980-487) for 10 min at room temperature (RT) and stained with
ER Staining Kit-Red Fluorescence (Abcam, #ab139482) following the manufacturer’s instructions.
Immunofluorescence was visualized by an Olympus BX53 microscope equipped with epifluorescence,
and photographs were taken (×40 objective) using a cooled camera device (ProgRes MF). ImageJ
(NIH) software [33] (http://imagej.nih.gov) was used to calculate the relative fluorescence from 40×
magnification images and normalized to cell size from phase-contrast images. At least 25 cells were
analyzed in duplicate for each group at the same exposure time.
2.4. RNA Extraction and Semi-Quantitative Reverse Transcription (RT)-PCR Analysis
Cells were harvested in TRIzol Reagent (Invitrogen, #15596026) and total RNA was isolated
following the manufacturer’s instructions. The first strand cDNA was synthesized from 2 µg of total
RNA with a MuLV reverse transcriptase kit (TermoFisher Scientific, #28025013). Semi-quantitative
Reverse-Transcribed (RT)-PCR was carried out by using Hot-Master Taq polymerase (Geneaid Biotech
Ltd., New Taipei City, Taiwan, #TQ050) with 2 µL cDNA reaction and genes specific oligonucleotides
under the conditions of linear amplification. The primers used for amplification of Xbp1s were as
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follows: Xbp1s-for GGAGTTAAGACAGCGCT; Xbp1s-rev TGTTCTGGAGGGGTGAC. PCR products
were run on a 2% agarose gel and visualized with ethidium bromide. The housekeeping 28S gene,
used as the internal standard, was amplified from the same cDNA reaction mixture. Densitometric
analysis was applied to quantify mRNA levels compared to control gene expression.
2.5. siRNA Interference
Subconfluent cells were plated in 35 mm Petri dishes and, the day after, were transfected with
control pSuper and pSuper-p53 (for p53 interference, si-p53) vectors [34] using the LipofectaminePlus
reagent (Invitrogen, #11514-015), according to the manufacturer’s instructions. Twenty-four hours
after transfection, cells were trypsinized and replated for the indicated experiments.
2.6. Western Blotting
Total cell extracts were prepared by incubation in a lysis buffer (50 mM Tris–HCl, pH 7.5, 150 mM
NaCl, 5 mM EDTA, 150 mM KCl, 1 mM dithiothreitol, and 1% Nonidet P-40) (all from Sigma-Aldrich)
and a mix of protease inhibitors (cOmpleteTM, Mini Protease Inhibitor Cocktail, Merck, Life Science S.r.l.,
Milan, Italy, #11836153001). Then, 15–30 µg of protein lysate was subjected to electrophoresis on 9–18%
SDS-PAGE gradient gels (Bio-Rad, #456-1095), according to the manufacturer’s instructions. The gels
were transferred to a polyvinylidene difluoride (PVDF) membrane (Immobilon-P, Millipore, #IPVH
00010) for 2 h in Tris-glycine buffer. Membranes were blocked in PBS-0.1% Tween 20 solution containing
3% BSA (Sigma-Aldrich) before probing with the following specific primary antibodies: mouse
monoclonal anti-p53 (1:1000) (DO-1, (1:100) (Santa Cruz Biotechnology Inc., Heidelberg, Germany;
sc-126,); rabbit polyclonal anti-BiP (1:1000) (Cell Signaling, C50B12 #3177); rabbit polyclonal anti-IRE1
alpha (p-Ser724) (1:1000) (Novus Biologicals, #NB100-2323SS); rabbit polyclonal anti-IRE1 alpha
(1:1000) (Novus Biologicals, #NB100-2324); rabbit polyclonal anti XBP1 (1:1000) (Novus Biologicals,
#NBP1-77681SS); and rabbit polyclonal anti-LC3B (1:1000) (Sigma-Aldrich, #L7543). Mouse monoclonal
anti-β-actin (1:10,000) (Sigma Aldrich, #A5441) was used as a protein loading control. Primary
antibodies were detected with the following horseradish peroxidase-labeled secondary antibodies: goat
polyclonal anti-mouse IgG-horseradish peroxidase (HRP, BioRad.; #172-1011) and anti-rabbit IgG-HRP
(BioRad; #172-1019). Enzymatic signals were visualized by chemiluminescence (ECL Detection system,
Amersham GE Healthcare, Milan, Italy, #RPN2106), according to the manufacturer’s protocol.
2.7. Statistical Analysis
Each experiment was performed at least three times. Results are expressed as values of mean ±
standard deviation (S.D.). Statistical significance was determined using Student’s t-tests for two sample
comparison. Difference was considered statistically significant when the p-value was at least <0.05.
3. Results
3.1. ER Stress Sis Activated by Zn(II)-Curc in mutp53H273 Cancer Cells
As Zn (II)-curc may induce mutp53 protein degradation through autophagy [14,15], and autophagy
can be induced by UPR activation [27], we investigated the effect of Zn(II)-curc on ER stress/UPR
activation. To address this issue, we used several approaches. U373 cells were treated with 100
µM Zn (II)-curc, the dose that induces mutp53 degradation and autophagy [14,15]. ER analysis
by specific fluorescent red labelling shows that Zn (II)-curc caused a marked increase in ER size
(Figure 1a,b). This increase correlated with the augmented expression of BiP/Grp78 as well as with
the IRE1α and p-IRE1α protein levels in both U373 and HT29 cells (Figure 1c,d), while the other
arms of the UPR were not affected in this experimental condition (not shown). Western blot and
semiquantitative RT-PCR evidenced spliced (s) Xbp1 mRNA (Figure 1c–e), in agreement with the
notion that activated IRE1α functions as an endoribonuclease, splicing a 26 base pair intron from Xbp1
mRNA [35]. The Zn (II)-curc-induced activation of IRE1α correlated with the reduction of mutp53
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expression levels (Figure 1c), while the p53 gene expression was not affected (Figure 1f). Interestingly,
the Zn (II)-curc treatment of T98 cells (expressing M237I p53 mutation), which we previously reported
not been affected by Zn (II)-curc at a biological level [12], did not increase BiP levels or reduced p53
protein levels (Supplementary Material Figure S1).
Figure 1. Zn (II)-curc induces endoplasmic reticulum (ER) stress in mutant p53H273-carrying cells.
(a) Representative photomicrographs of ER-Red Fluorescence staining in U373 cells untreated (Mock)
or treated with Zn (II)-curc (100 µg/mL) for 16 h (Original magnification: 40×). (b) Quantization of ER
content in U373 cells from ER-Red Fluorescence-stained cells. Mean fluorescence intensity (MFI) of
each individual cell was normalized to cell size and expressed as fold-change compared with untreated
cells at the same time point. Histograms represent the mean ± SD of three independent experiments.
* p ≤ 0.05. (c) Western blot analysis of p53, BiP, total (tot) IRE1α, phosphorylated (p) IRE1α, and XBP1
spliced (s) protein levels evaluated in U373 and HT29 cells untreated or treated with Zn (II)-curc (100
µg/mL) for 24 h. (d) Densitometric analysis was performed using Image J software to calculate the
ratio of the protein levels, as detected in (c), vs. β-actin. Histograms represent the mean ± SD of
three independent experiments. * p ≤ 0.05. (e) Total mRNA was extracted from U373 and HT29 cells
untreated or treated with Zn (II)-curc (100 µg/mL) for 24 h. Spliced (s) Xbp1 gene expression was
assayed by the polymerase chain reaction (PCR) of reverse-transcribed cDNA. Densitometric analysis
was performed using Image J software to calculate the Xbp1s/28S ratio. Histograms represent the mean
± SD of three independent experiments. * p ≤ 0.05. (f) p53 gene expression was assayed by PCR as in
(e). The p53/28S ratio is indicated.
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To further address the correlation between mutp53H273 degradation and ER stress activation,
wtp53-expressing cells were treated with Zn (II)-curc. As shown in Figure 2a, Zn(II)-curc did not increase
BiP expression levels or induce Xbp1 splicing (not shown) in wtp53-expressing cells, while it stabilized
endogenous wtp53 protein levels in accordance with previous studies where zinc supplementation
induced wtp53 oncosuppressor activities and the transcription of target genes such as p21, Puma,
and Bax [14,36]. On the contrary, both BiP (Figure 2b) and Xbp1 splicing (Figure 2c) were efficiently
induced in wtp53-expressing cells by Tunicamycin (Tn), a drug causing ER stress by inhibiting N-linked
glycosylation [37]. Altogether, these results indicate that the IRE1α/XBP1 arm of UPR was activated in
response to Zn (II)-curc only in mutp53H273 cells.
Figure 2. Zn (II)-curc does not affect ER stress in wtp53-carrying cells. (a) (left panels) Western blot
analysis of BiP and p53 protein levels in RKO and HCT116 cells treated with Zn(II)-curc (100 µg/mL) for
24 h. Densitometric analysis (right panels) was performed using Image J software to calculate the ratio
of BiP and p53 protein levels vs. β-actin. Histograms represent the mean ± SD of three independent
experiments. * p ≤ 0.05. (b) Western blot analysis of BiP protein levels in RKO and HCT116 cells treated
with Tunicamycin (Tn) (1 µg/mL) for 4 h. (upper panel) Densitometric analysis was performed using
Image J software to calculate the ratio of BiP protein levels vs. β-actin. Histograms represent the mean
± SD of three independent experiments. * p ≤ 0.05. (c) Total mRNA was extracted from RKO and
HCT116 cells treated with Tunicamycin (Tn) for 24 h, and Xbp1 gene expression was assayed by the
PCR of reverse-transcribed cDNA. Densitometric analysis was performed using Image J software to
calculate the Xbp1s/28S ratio. Histograms represent the mean ± SD of three independent experiments.
* p ≤ 0.05.
3.2. ER Stress/IRE1α Inhibition Impairs Zn(II)-Curc-Induced Autophagy and Mutp53 Degradation
To evaluate the role of ER stress/UPR activation in Zn (II)-curc-induced autophagy, we analyzed
the LC3I/II level (a cellular readout of autophagy) [18] by Western blot in U373 cells treated with
Zn (II)-curc with or without pre-treatment with 4-Phenyl butyric acid (PBA), a molecular chaperone
that dampens the ER stress [30]. The results show reduction of LC3II levels in the presence of 4-BPA,
concomitantly to the reduction of Zn (II)-curc-induced BiP protein levels (Figure 3a,b) and Xbp1
splicing (Figure 3c), suggesting that a possible autophagy inhibition was occurring following ER stress
inhibition, which is in agreement with the known role of Xbp1 splicing in triggering autophagy [38].
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Concomitantly, we verified the effect of ER stress inhibition on mutp53 levels and found that mutp53
protein was no longer downregulated in the presence of 4-BPA (Figure 3a,b).
Figure 3. ER stress inhibition impairs Zn (II)-curc-induced autophagy and mutp53 degradation.
(a) Western blot analysis of BiP, LC3I/II, and p53 protein levels in U373 cells untreated or treated
with Zn(II)-curc (100 µg/mL) for 24 h, with or without 1 h pre-treatment with 4-BPA (2.5 mM).
(b) Densitometric analysis was performed using Image J software to calculate the ratio of the protein
levels, as detected in (a), vs. β-actin. Histograms represent the mean ± SD of three independent
experiments. * p ≤ 0.05. (c) Total mRNA was extracted from U373 cells untreated or treated as in (a).
Spliced (s) and unspliced (u) Xbp1 gene expression were assayed by the PCR of reverse-transcribed
cDNA. Densitometric analysis was performed using Image J software to calculate the Xbp1s/28S ratio.
Histograms represent the mean ± SD of three independent experiments. * p ≤ 0.05.
Similarly, the inhibition of IRE1α-Xbp1 by the small molecule STF [31,32], which indeed
counteracted the Zn (II)-curc-induced Xbp1 splicing (Figure 4a) and slightly increased BiP levels
(Figure 4b,c), impaired the Zn (II)-curc-induced increase of LC3II levels and counteracted the
Zn (II)-curc-induced mutp53 downregulation (Figure 4b,c). Altogether, these results suggest
that the Zn (II)-curc-induced IRE1α-Xbp1 arm of the UPR was able to promote autophagy and
mutp53 downregulation.
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Figure 4. IRE1α inhibition impairs Zn (II)-curc-induced autophagy and mutp53 degradation. (a) Total
mRNA was extracted from U373 cells untreated or treated with Zn(II)-curc (100 µg/mL) for 24 h, with
or without inhibitor of XBP1 cleavage STF-083010 (STF) (60 µM). Spliced (s) and unspliced (u) Xbp1
gene expression was assayed by the PCR of reverse-transcribed cDNA. (lower panel) Densitometric
analysis was performed using Image J software to calculate the Xbp1s/28S ratio. Histograms represent
the mean ± SD of three independent experiments. * p ≤ 0.05. (b) Western blot analysis of p53, BiP,
and LC3I/II protein levels in U373 cells untreated or treated, as in (a). (c) Densitometric analysis was
performed using Image J software to calculate the ratio of the protein levels, as detected in (b), vs.
β-actin. Histograms represent the mean ± SD of three independent experiments. * p ≤ 0.05.
3.3. ER Stress or IRE1α Inhibition Reduces Zn(II)-Curc-Induced Cell Death
Next, we evaluated the role of ER stress/IRE1α activation on Zn (II)-curc-induced cell death.
To this aim, we combined Zn (II)-curc with either ER stress or IRE1α inhibitors. The results show that
both 4-BPA and STF efficiently reduced the Zn (II)-curc-induced cell death (Figure 5a,b), suggesting that
the activation of ER stress balanced the cell death/survival equilibrium towards cell death. Similarly,
the inhibition of wtp53 transcriptional activity with PFT-α (Figure 5a,b), as well as p53 knockdown
(Figure 5c), reduced the Zn (II)-curc-triggered cell death, in agreement with the effect of Zn(II)-curc on
the reactivation of wtp53 oncosuppressor functions, as previously reported [12,14,15]. Altogether, these
results suggest that both ER stress/UPR activation and wtp53 reactivation by Zn (II)-curc promoted cell
death in mutp53 cells.
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Figure 5. ER stress or IRE1α inhibition impair Zn (II)-curc-induced cell death. (a) Cell viability was
measured by trypan blue exclusion assay in U373 and HT29 cells untreated or treated with Zn (II)-curc
(100 µg/mL) for 24 h, with or without the inhibitor of XBP1 cleavage STF (60 µM), p53 inhibitor
PTF-α (30 µM), or 1 h pre-treatment with 4-BPA (2.5 mM), and expressed as percentage ± SD of three
independent experiments. * p ≤ 0.05 (combination treatments vs. Zn(II)-curc). (b) Cytofluorimetric
analysis of the SubG1 peak evaluated by Propidium Iodide (PI) staining of U373 and HT29 cells
untreated or treated as in (a) for 24 h. Percentage of apoptotic cells is shown ± SD of two independent
experiments. (c) U373 and HT29 cells were transfected with control pSuper (si-ctr) and pSuper-p53
(si-p53) vectors for p53 knockdown and 36 h after transfection, cells were treated with Zn(II)-curc
(100 µg/mL) for 24 h. Cell viability was measured by a trypan blue exclusion assay and expressed as
percentage ± SD of three independent experiments. * p ≤ 0.05.
3.4. Mutp53 Knockdown Abrogates the Zn(II)-Curc-Induced ER Stress
Finally, we asked whether Zn (II)-curc-induced mutp53 downregulation was upstream of the
ER stress or rather the consequence of UPR/autophagy activation. To address this issue, p53 was
knocked-down with siRNA, and ER stress was analyzed by several approaches. Analysis of ER by
immunofluorescence shows that the increase in ER size by Zn (II)-curc was abrogated in the U373 cells
undergoing p53 knockdown (Figure 6a); in agreement, the Zn (II)-curc-induced BiP protein levels
(Figure 6b) and Xbp1 splicing (Figure 6c) were strongly reduced by p53 knockdown in both U373 and
HT29 cells, suggesting that mutp53H273 degradation by Zn (II)-curc was likely upstream of the ER
stress/UPR activation.
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Figure 6. Mutp53 knockdown abrogates the Zn (II)-curc-induced ER stress. (a) U373 cells were
transfected with control pSuper (si-ctr) and pSuper-p53 (si-p53) vectors for p53 knockdown and 36 h
after transfection, cells were treated with Zn (II)-curc (100 µg/mL) for 16 h, before undergoing ER-Red
Fluorescence staining. Quantization of ER content in U373 cells from ER-Red Fluorescence-stained cells
as evaluated by the mean fluorescence intensity (MFI) of each individual cell normalized to cell size and
expressed as fold-change compared with untreated cells at the same time point. Histograms represent
the mean ± SD of three independent experiments. * p ≤ 0.05. (b) Western blot analysis of BiP and
p53 protein levels in U373 and HT29 cells transfected for 36 h with si-ctr and si-p53, and then treated
with Zn (II)-curc (100 µg/mL) for 24 h. Densitometric analysis was performed using Image J software
to calculate the ratio of BiP and p53 protein levels vs. β-actin, as indicated ns: not specific signal.
(c) Total mRNA was extracted from U373 cells treated as in (b), and spliced (s) and unspliced (u) Xbp1
gene expression were assayed by the PCR of reverse-transcribed cDNA. (upper panel) Densitometric
analysis was performed using Image J software to calculate the Xbp1s/28S ratio. Histograms represent
the mean ± SD of three independent experiments. * p ≤ 0.05.
4. Discussion
Cancer cells are often exposed to intrinsic and external factors that alter protein homeostasis.
The consequence is the activation of ER stress and UPR, which is the adaptive mechanism used to
cope with ER stress and to restore ER proteostasis [21]. Activation of the UPR through three different
but interconnected signaling pathways may favor pro-death or prosurvival signaling and is strictly
linked to autophagy. Autophagy is usually a prosurvival mechanism, playing a crucial role in drug
resistance, although it may also induce cell death [39,40]. The interplay between autophagy and UPR
and their abnormal activation may pave the way to degenerative and chronic diseases including
cancer [28,41]. Therefore, understanding the crosstalk between UPR activities and autophagy should
help in developing new treatment options for various pathologies, including cancer. Here, we found
that autophagy-mediated mutp53H273 degradation following zinc supplementation correlated with
activation of ER stress and of the IRE1α/XBPI arm of the UPR. ER stress or IRE1α/XBPI inhibition
impaired mutp53 degradation and reduced cell death, suggesting that both ER stress/UPR activation
and the clearance of mutp53 by zinc played a pro-death role in mutp53-carrying cells, as summarized
in Figure 7.
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Figure 7. Schematic representation of the interplay between ER stress/unfolded protein response (UPR)
activation and autophagy in response to Zn (II)-curc in mutp53H273-carrying cancer cells. Diagram
illustration describes the pathways contributing to mutp53H273 degradation by autophagy and the
role of ER stress/UPR activation. The arrows indicate activation, and the red lines indicate blocking.
The possible starting even could be the Zn-induced mutp53 folding/unfolding balance, as previously
reported [8,11,36,37].
Mutp53 proteins may acquire a misfolded conformation forming hyperstable micro- and
macro-aggregates that cannot undergo degradation, with consequent accumulation in tumors [5].
This aggregation may result from the loss or alteration of DBD-bound zinc, which is necessary
for the thermodynamic stability of the DBD, and is needed for wtp53 oncosuppressor function [6].
Our previous studies demonstrated that zinc supplementation was able to modify the equilibrium
between the p53 mutant and wild-type conformation, positively reactivating wtp53 functions of some
of the most frequently p53 mutated residues, such as Arg175 and Arg273 [9–12,14,42,43], which is in
line with the findings that zinc metallochaperone rescues mutant p53 conformation [44]. Based on these
findings, here we can speculate that the effect of zinc on mutp53 folding/unfolding unbalance could act
as a cellular stress to trigger UPR activation. Thus, the depletion of mutp53 failed to recapitulate the
effect of zinc on UPR activation, and zinc did not activate UPR in wtp53-carrying cells. In addition,
zinc treatment of cells carrying a different mutant p53 protein (i.e, M237I) did not induce mutp53
degradation or trigger UPR activation. Therefore, we can reasonably affirm that the UPR activation by
zinc is linked to the degradation of the mutp53 protein and, in particular, of mutp53H273. However,
further studies are needed to unveil the mechanisms that are involved in UPR activation by degradation
of some mutp53 proteins by zinc.
UPR activation is commonly observed in various tumor specimens and correlates with drug
resistance [45]. UPR is orchestrated by three main sensors, and our data show that the IRE1α-XBP1
arm of UPR was mainly activated during mutp53 degradation through autophagy, likely in an
autoregulatory loop, although the exact mechanism by which mutp53 degradation increases ER
stress-induced activation of IRE1α/XBPI remains to be defined. The IRE1α-XBP1 pathway is the
most conserved signaling branch of the UPR and plays important roles in both physiological and
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pathological settings, with its activity having profound effects on disease progression and prognosis [35].
The IRE1α signaling pathway induces the expression of the transcription factor Xbp1s, which increases
the expression of ER chaperones and ER mass, stimulates lipid biogenesis, and degrades unfolded
proteins to enhance the secretory function of ER and triggers autophagy initiation, mainly serving as a
pro-survival pathway in multiple human cancers [35]. XBP1 pathway activation has been shown to
induce triple-negative breast cancer progression and is correlated with poor patient survival, suggesting
that UPR inhibitors in combination with chemotherapy may improve tumor regression [46]. In addition,
unspliced XBP1 is associated with longer survival of breast cancer patients treated with tamoxifen,
which is opposite to XBP1 splicing that is associated with shorter survival [47]. Therefore, developing
combination therapies that target specific UPR signaling pathways will hopefully bypass anticancer
drug resistance. On the other hand, we found here that XBP1 inhibition impaired zinc-induced
autophagy and mutp53 degradation, indicating that UPR modulation may achieve different effects
depending on cell context. To make the story more complex, mup53 has been shown to favor cancer
cell survival and promote cancer progression by its crosstalk with cellular stress pathways [48].
For instance, the downregulation of mutp53 interferes with the downstream activation of the cross-talk
between NRF2 and p62, restoring the cytotoxic effect of chemotherapies [49], and mutp53 inhibits the
pro-apoptotic and pro-survival UPR effectors PERK and ATF6 in cancer cell lines [50], suggesting that
UPR inhibitors combined with mutp53 inhibitors may increase cell death.
5. Conclusions
In conclusion, this study demonstrates for the first time that a curcumin-based zinc complex was
able to induce UPR activation to trigger autophagy and mutp53H273 degradation, highlighting the
interplay between ER stress and autophagy. As UPR activation has both pro-survival and pro-death
effects, caution is necessary in the design of therapies that target UPR components in combination with
chemotherapies to increase the antitumor response, as they could hamper mutp53 degradation.
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